[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":279},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,40,70,97,119,141,166,198,227,253],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100643161","national-study-on-the-prevalence-of-catheter-related-venous-thrombosis-100643161",false,"NCT07643246","National Study on the Prevalence of Catheter-Related Venous Thrombosis","TROMBO","Inclusion Criteria:\n\n* All hospitalized patients aged ≥18 years from all hospital wards, including critical care units, who are carriers of a midline, FICC, PICC, or CICC catheter with a dwell time of at least 7 days will be included.\n\nExclusion Criteria:\n\n* Patients who do not provide informed consent for the ultrasound assessment.",true,"ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","1 Day","OBSERVATIONAL","The aim is to determine the prevalence of catheter-related thrombosis (CRT) in hospitalized patients carrying PICC, FICC, CICC, and midline catheters through a multicenter, standardized prevalence study. To achieve this, a cross-sectional study with prospective data collection will be conducted, including, through consecutive sampling to minimize selection bias, all hospitalized patients over 18 years of age from both general wards and critical care units who have had one of these catheters in place for at least 7 days. During data collection, an ultrasound examination of the catheter insertion site will be performed in order to rule out the presence of thrombotic complications.",[26,27],"Thrombosis","Venous Catheterization","NOT_YET_RECRUITING","2026-06-08",{"date":31,"type":32},"2026-06-11","ACTUAL",{"date":34,"type":21},"2026-05-25",{"date":36,"type":21},"2026-06-19",{"name":38,"class":39},"Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100639678","ivr-on-upper-limb-rehabilitation-in-stroke-patients-a-clinical-trial-100639678","NCT07609966","IVR ON UPPER-LIMB REHABILITATION IN STROKE PATIENTS: A CLINICAL TRIAL","Impact of Immersive Virtual Reality in the Rehabilitation in the Acute Phase of Stroke: a Clinical Study and Correlation With Blood Biomarkers and Polymorphisms Related to Neuroplasticity","REVICTUS","Inclusion Criteria: Diagnosis of ischemic stroke or intracerebral hemorrhage. Age \\> 18 years. \\\u003C 7 days between stroke onset and inclusion in the study. Impairment of mobility in the right or left upper limb due to stroke. After hospital discharge, patients continue an intensive conventional rehabilitation (ICR) program at their referral rehabilitation center (MUTUAM).\n\nAbility to understand and sign the study informed consent form (ICF) and the IDIBGI Biobank informed consent form.\n\n\\-\n\nExclusion Criteria:\n\nPrevious upper limb disability (neurological or non-neurological cause). Previous dementia or any disease with a life expectancy of less than 1 year. Language comprehension difficulties. Difficulty remembering exercise instructions. History of photosensitive epilepsy.\n\n\\-",{"count":49,"type":21},120,"INTERVENTIONAL",[52],"NA","Stroke is the leading cause of acquired disability in adults. Neurorehabilitation aims to recover the affected function by stimulating neuroplasticity. Immersive virtual reality (IVR) has shown that it can be effective but the evidence is still weak. Similarly, few studies have analysed blood biomarkers as outcome or predictive indicators, and knowledge of the influence of genetic polymorphisms on rehabilitation efficacy is limited. Our objectives are (1) to demonstrate that the addition of IVR to conventional rehabilitation (CR) improves upper-limb motor function, functional status, and quality of life in stroke patients, at short and long term; (2) to determine the effect of IVR on the expression of neuroplasticity biomarkers at long term; (3) to evaluate the impact of genetic polymorphisms on the rehabilitation and functional prognosis of treated patients, at short and long term; and (4) to identify acute phase predictive biomarkers of motor recovery and functional prognosis at short and long term. To this end, we propose a single-center, prospective, randomised, controlled, and open label clinical trial with blinded end-point assessment. Adults diagnosed of acute ischaemic\u002Fhaemorrhagic stroke with mobility impaired in the upper-limb and included in a program of intensive CR (ICR) at hospital discharge will be included. Patients will be randomly assigned into two groups: ICR+IVR or only ICR and will be followed for one year to assess, at 3 and 12 months, motor strength in the upper-limb, functional dependence and quality of life. In blood samples obtained at admission (baseline) and at 12 months, proteins and microRNAs will be analysed to identify predictive biomarkers of recovery (motor and functional) and to determine the effect of IVR on neuroplasticity mechanisms. Genetic polymorphisms that may affect motor and functional recovery of patients treated with RC±RVI will also be analysed",[55],"Stroke Acute",[57,58,59],"stroke","virtual reality","rehabilitation","RECRUITING","2026-05-20",{"date":63,"type":32},"2026-05-27",{"date":65,"type":32},"2022-08-31",{"date":67,"type":21},"2026-06",{"name":38,"class":39},1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":78,"maxAge":4,"enrollmentInfo":79,"targetDuration":81,"studyType":23,"phases":4,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":69},"100582947","adipose-tissue-gene-expression-and-metabolomics-links-to-the-gut-microbiome-brain-axis-100582947","NCT06869941","Adipose Tissue Gene Expression and Metabolomics Links to the Gut Microbiome-brain Axis","Adipose Tissue Gene Expression and Metabolomics Links to the Gut Microbiome-brain Axis (POINSETTIA Study)","POINSETTIA","Inclusion Criteria:\n\n* Men and women \\>20 years old.\n* Scheduled for surgical intervention to extract adipose tissue.\n* Signed informed consent for study participation.\n\nExclusion Criteria:\n\n* Not meeting inclusion criteria.\n* Non-obesity-related systemic diseases (cancer, severe kidney\u002Fliver disease).\n* Systemic diseases with intrinsic inflammation (rheumatoid arthritis, Crohn's disease, asthma, chronic infections (HIV\u002Ftuberculosis)) or any type of infectious disease.\n* Pregnant\u002Fbreastfeeding women.\n* Persons under legal\u002Fadministrative restrictions.\n* Those with infection symptoms in the past month.\n* Use of antibiotics\u002Fantifungals\u002Fantivirals (previous 3 months).\n* Chronic steroidal\u002Fanti-inflammatory drug use.\n* Major psychiatric history.\n* Excessive alcohol intake, acute or chronic (\\>40g\u002Fday (women), \\>80g\u002Fday (men)) or drug abuse.\n* Immunosuppressants treatment.\n* Participants with severe eating disorders.\n* Serum liver enzymes (GOT, GPT) above twice the upper limit of normal. Obvious signs or symptoms of liver disease, acute or chronic hepatitis.\n* History of iron balance disorders (e.g., genetic hemochromatosis, hemosiderosis from any cause, atransferrinemia, paroxysmal nocturnal hemoglobinuria).\n* Creatinine greater than 1.2 and glomerular filtration rate below 40.\n* Current treatment for malignant neoplasia, other than basal cell or squamous cell skin cancer.\n* Heart disease classified as class III or IV, known ischemic cardiovascular disease.\n* Renal failure, history of kidney transplant, or current dialysis treatment.\n* Chronic constipation (bowel movement frequency ≥ 7 days) .","20 Years",{"count":80,"type":21},100,"1 Month","This study aims to understand how adipose tissue (fat) and the gut microbiota (the bacteria in the gut) may influence brain function and cognition. It has been observed that changes in adipose tissue in animals such as mice and Drosophila (a type of insect) affect memory and other brain functions. Additionally, it is believed that the gut microbiota also plays an important role in cognition.\n\nThis study will explore how gene expression in adipose tissue, blood metabolites, and the gut microbiota are related to cognitive function, such as memory and thinking, in individuals with and without obesity. The investigation will also assess whether these factors can predict changes in the brain over time and how they influence sleep, physical activity, and blood sugar regulation.\n\nAdvanced technologies will be used to analyze samples of tissue, blood, and microbiota, with the goal of identifying new mechanisms through which obesity affects the brain. This research may contribute to the development of new diagnostic and therapeutic strategies for cognitive problems in individuals with obesity.",[84],"Obesity",[86,87,88],"Continous Glucose Monitoring","Cognition","Gut-microbiota-brain axis","2026-03-26",{"date":91,"type":32},"2026-03-31",{"date":93,"type":32},"2025-08-05",{"date":95,"type":21},"2027-01-31",{"name":38,"class":39},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":16,"sex":17,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":114,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":118,"locationsCount":69},"100488960","involvement-of-the-gut-microbiota-brain-cross-talk-in-the-loss-of-eating-control-100488960","NCT05646901","Involvement of the Gut Microbiota-brain Cross-talk in the Loss of Eating Control","Involvement of the Gut Microbiota-brain Cross-talk in the Loss of Eating Control (GMBCrossTalkFood)","GMBTalk-Food","Inclusion Criteria:\n\n1. Men and women aged 30-65 years.\n2. Informed consent for participation in the study.\n\nExclusion Criteria:\n\n1. Serious systemic disease unrelated to obesity such as cancer, severe kidney, or liver disease, known as type 1 or type 2 diabetes.\n2. Systemic diseases with intrinsic inflammatory activity such as rheumatoid arthritis, Crohn's disease, asthma, chronic infection (e.g., HIV, active tuberculosis), or any type of infectious disease.\n3. Pregnancy and lactation.\n4. Patients with severe disorders of eating behavior.\n5. Persons whose liberty is under the legal or administrative requirement.\n6. Clinical symptoms and signs of infection in the previous month.\n7. Antibiotic, antifungal or antiviral treatment in the previous 3 months.\n8. Anti-inflammatory chronic treatment with steroidal and\u002For non-steroidal anti-inflammatory drugs.\n9. Major psychiatric antecedents.\n10. Excessive alcohol intake, either acute or chronic (alcohol intake greater than 40 g a day (women) or 80 g\u002Fday (men)) or drug abuse.\n11. Serum liver enzyme (AST, ALT) activity over twice the upper limit of normal.\n12. History of disturbances in iron balance (e.g., genetic hemochromatosis, hemosiderosis from any cause, atransferrinemia, paroxysmal nocturnal hemoglobinuria).\n13. Creatinine greater than 1.2 and glomerular filtration rate less than 40.\n14. Immunosuppressants treatment.\n15. Chronic constipation (depositional habit ≥ 7 days)\n16. Kidney failure, history of a kidney transplant, or current treatment with dialysis.\n17. Treatment with a slimming product during the previous two months.\n18. Class III or IV heart failure (according to the New York Heart Association), medical records of ischemic cardiovascular disease.\n19. Current treatment for malignant neoplasm.","30 Years","65 Years",{"count":108,"type":21},116,"Overweight and obesity are increasingly prevalent worldwide. These bodyweight disorders are closely related to deficiencies in the control of food intake. A potential yet unexplored mechanism to explain the loss of eating control is the interaction between the gut microbiota and the brain. The mechanisms underlying the communication between the gut microbiome and the host remain largely unexplored. These mechanisms could occur in part through small non-coding RNAs, called microRNAs (miRNAs). miRNAs regulate epigenetic mechanisms to control gene expression.\n\nTwo hypotheses have been proposed:\n\nI. The interaction between the gut microbiota and the brain and its associated epigenetic changes play an important role in the overweight-related loss of eating control and metabolic imbalance.\n\nII.The composition and functionality of the gut microbiota are associated with circulating microRNAs and glycemic variability and modify the effect of physical activity on cognitive parameters and brain microstructure (R2\\*).\n\nThe study includes a cross-sectional design (comparison of subjects with and without obesity) to evaluate parameters associated with food addiction through validated questionnaires. The metabolic and behavioral profiles of the cohort will be characterized. The medial prefrontal cortex connectivity will be studied using functional magnetic resonance imaging (fMRI). The composition and functionality of the gut metagenome of the subjects will be analyzed in association with metabolic and behavioral parameters and imaging data. miRNAs can act as mediators of epigenomics of the effects of the metagenome that impact the brain, therefore it will be analyzed a broad profile of miRNAs circulating in plasma.",[84],[86,87,112,113],"Brain Iron content","microRNA",{"date":91,"type":32},{"date":116,"type":32},"2022-12-12",{"date":95,"type":21},{"name":38,"class":39},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":50,"phases":129,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":69},"100631543","evaluation-of-the-perfusion-of-the-pancreatic-remnant-with-indocyanine-green-and-its-impact-on-the-reduction-of-pancreatic-fistula-after-pancreaticoduodenectomy-100631543","NCT07502053","Evaluation of the Perfusion of the Pancreatic Remnant With Indocyanine Green and Its Impact on the Reduction of Pancreatic Fistula After Pancreaticoduodenectomy","Evaluation of the Perfusion of the Pancreatic Remnant With Indocyanine Green and Its Impact on the Reduction of Pancreatic Fistula After Pancreaticoduodenectomy: A Randomized Pilot Study","INDOPANC","Inclusion Criteria:\n\n* Patients for whom a Cephalic Pancreaticoduodenectomy is indicated.\n* Age over 18 years.\n* Informed consent (IC) signed by the patient and the investigator\n\nExclusion Criteria:\n\n* Patients in whom it was not possible to perform a pancreaticojejunal anastomosis using the Blumgart technique.\n* Patients in whom an additional procedure was required during surgery, such as the resection of other organs.\n* Patients in whom resection was ruled out during surgery.\n* Allergy to iodine or shellfish.\n* Patients with psychiatric illnesses, addictions, or any disorder that prevents understanding of the informed consent (IC).",{"count":128,"type":21},40,[52],"Postoperative pancreatic fistula (POPF) is the most common complication following cephalic duodenopancreatectomy (DPC) and is a key determinant of severe postoperative morbidity and mortality. Despite numerous trials aimed at reducing POPF incidence, it remains high, ranging between 3% and 45%. The exact pathophysiology of pancreatic fistulas is not fully understood, but studies suggest that they may be related to pancreatic hypoperfusion after surgery, leading to ischemia, inflammation, pancreatitis, and failure of pancreatic anastomosis. Few studies focus on improving anastomotic failure through pancreatic perfusion, though ensuring adequate blood supply to the pancreas has shown promise in reducing failure rates.\n\nIndocyanine Green (ICG) has been widely used in various surgical fields to assess organ perfusion, including gastrointestinal, plastic, neuro, hepatic, and vascular surgeries, but it is underutilized in pancreatic surgery. ICG has shown potential to improve surgical outcomes, reduce perioperative morbidity, and decrease hospitalization costs. In the context of DPC, ICG could help assess pancreatic perfusion and identify areas of hypoperfusion, guiding the surgeon to extend resections to well-perfused areas. In summary, using ICG could potentially decrease the incidence of pancreatic fistulas, improve patient outcomes, reduce hospital stays, and lower the overall cost of patient care.",[132],"Postoperative Pancreatic Fistula Post-pancreatoduodenectomy","2026-03-24",{"date":135,"type":32},"2026-03-30",{"date":137,"type":32},"2024-06-15",{"date":139,"type":21},"2027-06-15",{"name":38,"class":39},{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":150,"conditions":151,"keywords":154,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":69},"100432022","3d-laparoscopic-adrenalectomies-for-adrenal-tumors-100432022","NCT04905706","3D Laparoscopic Adrenalectomies for Adrenal Tumors","Three-dimensional Laparoscopic Adrenalectomies for Benign and Malignant Adrenal Tumors","Inclusion Criteria:\n\n* All adult patients (age ≥ 18 years)\n* Patients diagnosed with adrenal masses (benign and malignant tumors)\n* Underwent a unilateral 3D laparoscopic adrenalectomy from January 2013 to December 2033.\n\nExclusion Criteria:\n\n* Emergency surgery.\n* Open adrenalectomy.\n* Bilateral adrenalectomies (open or laparoscopy).\n* Patients who underwent laparoscopic adrenalectomy together with another laparoscopic surgical procedure in the same intervention.\n* Patients without complete follow-up for at least 30 days after hospital discharge.",{"count":149,"type":21},300,"The main drawbacks of conventional 2D laparoscopy are limited depth perception and loss of spatial orientation. High-quality 3D laparoscopy systems might improve surgical outcomes for adrenalectomy.",[152,153],"Adrenal Tumor","Adrenalectomy; Status",[155,156,157],"Three-dimensional laparoscopy","Adrenal tumors","3D laparoscopic adrenalectomy","2025-05-06",{"date":160,"type":32},"2025-05-09",{"date":162,"type":32},"2013-01-01",{"date":164,"type":21},"2033-12-31",{"name":38,"class":39},{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":174,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":50,"phases":178,"briefSummary":179,"conditions":180,"keywords":184,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":197},"100463781","the-effect-of-the-movement-imitation-therapy-in-preterm-mit-pb-in-motor-behaviors-quality-100463781","NCT05319158","The Effect of the Movement Imitation Therapy in Preterm (MIT-PB) in Motor Behavior's Quality.","The Effect of the Movement Imitation Therapy for Preterm Babies (MIT-PB) on Motor Behavior Quality. Quasi-experimental Design.","MIT-PB","Inclusion Criteria:\n\n* Preterm infants born before 32w GA and less than 1500g weight.\n* Infants who show Abnormal General Movements (CS-PR pattern) at 34-36w postmenstrual age (PMA).\n* Families able to understand\u002Fspeak Catalan, Spanish or English.\n* Families willing to participate who have the informed consent\n\nExclusion Criteria:\n\n* Infants with congenital abnormalities and\u002For genetic disorders\n* Infants with invasive ventilation or Continuous Positive Airway Pressure (CPAP) at 36 weeks PMA.\n* Infants with Normal General Movements at 34-36 w PMA.\n* Families not willing to participate.","22 Weeks","32 Weeks",{"count":177,"type":21},36,[52],"This study aims to assess the effect of a parent-administered intervention program based on MIT-PB in preterm with abnormal general movements during the preterm period. We will describe the short and long-term differences between infants exposed to MIT-PB and infants who follow current standard care.",[181,182,183],"Premature Birth","Risk","Early Intervention",[185,186,187,188],"neonatal therapy","general movements","high risk neurodevelopment","physiotherapy","2024-12-05",{"date":191,"type":32},"2024-12-10",{"date":193,"type":32},"2022-04-04",{"date":195,"type":21},"2027-03-31",{"name":38,"class":39},3,{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":50,"phases":208,"briefSummary":209,"conditions":210,"keywords":214,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":69},"100532994","comparing-pp-and-pvdf-meshes-in-midline-laparotomy-closure-for-high-risk-colorectal-surgery-impact-on-incisional-hernia-and-surgical-wound-infection-100532994","NCT06220045","Comparing PP and PVDF Meshes in Midline Laparotomy Closure for High-risk Colorectal Surgery. Impact on Incisional Hernia and Surgical Wound Infection.","Comparison Between the Use of a Polypropylene (PP) Prophylactic Mesh and a Polyvinylidene Fluoride (PVDF) Mesh in the Closure of Midline Laparotomy in Emergency Colorectal Surgery for High-risk Patients of Incisional Hernia. Impact on Surgical Wound Infection.","PROFIMESH","Inclusion Criteria:\n\n* Patients diagnosed with colorectal pathology requiring urgent surgical treatment via midline laparotomy.\n* Patients undergoing urgent laparoscopic surgery but requiring conversion to midline laparotomy.\n* Need for urgent surgical treatment involving the colon and\u002For rectum, even in the presence of other abdominal pathologies.\n* Age over 18 years.\n* Signed informed consent (IC) from both the patient and the investigator\n* Severe chronic obstructive pulmonary disease (COPD) according to the GOLD classification or decompensated COPD.\n* BMI ≥ 35 kg\u002Fm2.\n* Re-laparotomies.\n\nExclusion Criteria:\n\n* Patients with psychiatric illnesses, addictions, or any disorder hindering the understanding of the Informed Consent.\n* Inability to read or comprehend any of the languages in the Informed Consent (Catalan, Spanish).",{"count":207,"type":21},60,[52],"In the latest guidelines for abdominal wall closure in emergency surgery published in the World Journal of Emergency Surgery (WJES) in 2023, no specific recommendations are made in this regard.\n\nCurrent literature does not provide any articles comparing these two types of mesh materials (PP vs PVDF) in emergency colorectal surgery. It is necessary to conduct a study comparing these two types of mesh materials, specifically in high-risk patients for incisional hernia and emergency colorectal surgery. This study aims to contribute to generating evidence regarding differences in wound infection incidence and potential subsequent complications, such as chronic pain.\n\nIt is essential to conduct a study comparing different methods of laparotomy closure, specifically in emergency colorectal surgery, to contribute valuable evidence regarding the incidence of incisional hernia and potential subsequent complications.",[211,212,213],"Colorectal Cancer","Wound Infection","Hernia Incisional",[215,212,213,216,217,218],"Colorectal cancer","Mesh","Polypropylene","PVDF","2024-10-06",{"date":221,"type":32},"2024-10-08",{"date":223,"type":32},"2024-02-01",{"date":225,"type":21},"2025-01-15",{"name":38,"class":39},{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":50,"phases":236,"briefSummary":238,"conditions":239,"keywords":241,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":69},"100550175","phase-3-benefits-of-inhalation-of-hypertonic-saline-solution-prior-to-physiotherapy-eltgol-technique-in-bronchiectasis-100550175","NCT06443658","Benefits of Inhalation of Hypertonic Saline Solution Prior to Physiotherapy ELTGOL Technique in Bronchiectasis","Benefits of Inhalation of Hypertonic Saline Solution Prior to ELTGOL Physiotherapy in Bronchiectasis","Inclusion Criteria:\n\n* Adult patients with bronchiectasis confirmed by high resolution computed tomography\n* No exacerbations in the previous month\n* Chronic mucopurulent and purulent sputum\n* ≥10ml daily expectoration\n* At least one exacerbation in the previous year\n* (Forced expiratory volume the 1st second) FEV1 ≥30% after bronchodilation\n* Sign the informed consent\n\nExclusion Criteria:\n\n* Current smokers or a smoking history of ≥20 p-y\n* Asthma, allergic bronchopulmonary aspergillosis or Cystic Fibrosis\n* Pregnant or lactating women\n* Following mucoactive treatment in the previous month\n* Inability to perform ELTGOL, spirometry or to attend visits\n* Practicing pulmonary rehabilitation in the previous 6 months\n* Change of treatment the previous month\n* Uncontrolled hypertension",{"count":235,"type":21},57,[237],"PHASE3","Bronchiectasis is a chronic bronchial disease in which the usual capacity to remove secretions does not function correctly, causing mucus retention that leads to chronic infection. As with all infections, the use of antibiotics and puss removal are essential treatment elements. Physiotherapeutic techniques are used to assist in the removal of secretions, although these are time-consuming practices that need to be much better studied and which patients often do not continue practicing diligently. A physiotherapeutic technique called (Slow prolonged expiration in lateral decubitus) ELTGOL has been shown to be somewhat effective but as the mucus is viscous in this disorder, it can be difficult to get it to move. It is thought that saline solution inhalations may reduce mucus viscosity and could help to ease expectoration, facilitating the removal of the mucus by the physiotherapeutic technique. This project aims to test this hypothesis, which if true could represent an advance in the treatment of this severely debilitating disease.",[240],"Bronchiectasis Adult",[242,243,244],"airway clearance","hypertonic saline","respiratory physiotherapy","2024-07-02",{"date":247,"type":32},"2024-07-03",{"date":249,"type":32},"2024-06-01",{"date":251,"type":21},"2027-12",{"name":38,"class":39},{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":263,"conditions":264,"keywords":266,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":69},"100550065","selection-of-surgical-technique-in-rectal-cancer-100550065","NCT06442215","Selection of Surgical Technique in Rectal Cancer","Selection of Surgical Technique in Rectal Cancer Through the Development of a Predictive Model for Optimal Oncological Outcomes","TECARE","Inclusion Criteria:\n\n* Scheduled surgery for anterior resection of the rectum meeting oncological criteria with mesorectal excision.\n* Age ≥ 18 years.\n* Histology of adenocarcinoma with or without neoadjuvant chemotherapy or chemoradiotherapy.\n* Initial stage T1-T4a. Any N. Any M.\n* Intention for R0 resection.\n\nExclusion Criteria:\n\n* Colorectal tumor with histology different from adenocarcinoma.\n* Synchronous colon tumor.\n* Benign pathology or adenoma.\n* Tis.\n* T4b or oncological multivisceral resections.\n* History of neoplastic colorectal surgery or local excision or TAMIS.\n* Perforated or obstructive rectal neoplasm.",{"count":262,"type":21},333,"Currently, there is no prediction scale available to identify patients with rectal neoplasms as technically complex in the middle and lower thirds; that is, those who are at high risk of affected circumferential margins and low quality of the mesorectum. The application of a predictive model that allows preoperative identification of the group of patients in whom optimal results in mesorectal quality and circumferential margin are less likely to be obtained through laparoscopic or minimally invasive surgery would enable the selection of patients who will require and justify all efforts and healthcare resources to improve surgical outcomes.\n\nTherefore, the investigators aim to create a predictive model to identify these patients, allowing the discrimination of which patients will benefit from different techniques, or even which ones would be opportune to initially consider an open approach.",[265],"Rectal Neoplasms",[267,268,269,270],"Rectal cancer","Surgery","Minimal invasive surgery","Oncological outcomes","2024-06-04",{"date":273,"type":32},"2024-06-05",{"date":275,"type":32},"2024-04-03",{"date":277,"type":21},"2026-04-03",{"name":38,"class":39},""]